931 related articles for article (PubMed ID: 30266805)
1. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
2. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
Kim M; Kim M; Park SJ; Lee C; Lim DS
EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
[TBL] [Abstract][Full Text] [Related]
3. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
4. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
[TBL] [Abstract][Full Text] [Related]
5. Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein.
Li C; Srivastava RK; Elmets CA; Afaq F; Athar M
Biochem Biophys Res Commun; 2013 Sep; 438(4):607-12. PubMed ID: 23942117
[TBL] [Abstract][Full Text] [Related]
6. Angiomotins link F-actin architecture to Hippo pathway signaling.
Mana-Capelli S; Paramasivam M; Dutta S; McCollum D
Mol Biol Cell; 2014 May; 25(10):1676-85. PubMed ID: 24648494
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
8. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
9. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation.
Chan SW; Lim CJ; Guo F; Tan I; Leung T; Hong W
J Biol Chem; 2013 Dec; 288(52):37296-307. PubMed ID: 24225952
[TBL] [Abstract][Full Text] [Related]
10. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
12. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
[TBL] [Abstract][Full Text] [Related]
13. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development.
Hong W
Sci Signal; 2013 Sep; 6(291):pe27. PubMed ID: 24003252
[TBL] [Abstract][Full Text] [Related]
14. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
[TBL] [Abstract][Full Text] [Related]
15. MOB1 Mediated Phospho-recognition in the Core Mammalian Hippo Pathway.
Couzens AL; Xiong S; Knight JDR; Mao DY; Guettler S; Picaud S; Kurinov I; Filippakopoulos P; Sicheri F; Gingras AC
Mol Cell Proteomics; 2017 Jun; 16(6):1098-1110. PubMed ID: 28373298
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
17. Structural and Biochemical Analyses of the Core Components of the Hippo Pathway.
Ni L; Luo X
Methods Mol Biol; 2019; 1893():239-256. PubMed ID: 30565138
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis.
Dai X; She P; Chi F; Feng Y; Liu H; Jin D; Zhao Y; Guo X; Jiang D; Guan KL; Zhong TP; Zhao B
J Biol Chem; 2013 Nov; 288(47):34041-34051. PubMed ID: 24106267
[TBL] [Abstract][Full Text] [Related]
19. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
20. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP).
Oka T; Mazack V; Sudol M
J Biol Chem; 2008 Oct; 283(41):27534-27546. PubMed ID: 18640976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
